Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases

Angiogenesis

Volumn 5, Issue 3, 2002, Pages 191-201

  Kim, Tae H ^a   Kim, Eunkyung ^a   Yoon, Dongwon ^a   Kim, Jaebeum ^a   Rhim, Tai Y ^a   Kim, Soung S ^a  

^a Yonsei University   (South Korea)

Author keywords

Angiogenesis inhibition; Basic fibroblast growth factor; Bovine capillary endothelial cell; Prothrombin kringles; Tumor metastases

Indexed keywords

PROTHROMBIN; RECOMBINANT PROTHROMBIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CELL GROWTH; CHORIOALLANTOIS; EMBRYO; ENDOTHELIUM CELL; ESCHERICHIA COLI; KRINGLE DOMAIN; LEWIS CARCINOMA; MALE; METASTASIS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; TUMOR GROWTH;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; BASE SEQUENCE; CAPILLARIES; CATTLE; CELL DIVISION; CLONING, MOLECULAR; DNA PRIMERS; ENDOTHELIUM, VASCULAR; ESCHERICHIA COLI; FIBROBLAST GROWTH FACTOR 2; HUMANS; KRINGLES; LUNG NEOPLASMS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROTHROMBIN; RECOMBINANT PROTEINS;

ANIMALIA; BOVINAE; ESCHERICHIA COLI;

EID: 0038516807     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023835102832     Document Type: Article

References (43)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
2. Folkman J, D'Amore P. Blood vessel formation: What is its molecular basis? Cell 1996; 87: 1153-5.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
5. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
6. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-64.
7. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
8. Cao R, Wu HL, Vwitonmaki N et al. Suppression of angiogenesis and tumor growth by the inhibitor K 1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999; 96: 5728-33.
9. Kandel J, Bossy-Wetzel E, Radvanyi F et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991; 66: 1095-104.
10. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
11. Nguyen M, Watanabe H, Budson AE et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356-61.
12. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824-31.
13. Cao Y, Ji RW, Davidson D et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996; 271: 29461-7.
14. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-53.
15. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
16. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
17. Ji WR, Castellino FJ, Chang Yet al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998; 12: 1731-8.
18. Cao Y, Chen A, An SSA et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997; 272: 22924-8.
19. Clapp C, Martial JA, Guzman RC et al. The 16-kilodalton N- terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993; 133: 1292-9.
20. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 1995; 92: 7799-803.
21. Brooks PC, Silletti S, Schalscha TL et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400.
22. Cao Y. Endogenous angiogenesis inhibitors and their theraupetic implications. Int J Biochem Cell Biol 2001; 33: 357-69.
23. Rhim T, Park C-S, Kim E, Kim SS. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem Biophys Res Commun 1998; 252: 513-6.
24. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 1988; 57: 915-56.
25. Mann KG, Nesheim ME, Church WR et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
26. Lee TH, Rhim T, Kim SS. Prothrombin kringle 2 domain has growth inhibitory activity against bFGF-stimulated capillary endothelial cell. J Biol Chem 1998; 273: 28805-12.
27. Rhim T, Kim E, Park C-S, Kim SS. Expression, purification, and characterization of prothrombin kringle 2. J Biochem Mol Biol 1999; 31: 156-60.
28. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
29. Sim BKL, O'Reilly MS, Liang H et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997; 57: 1329-34.
30. Cao Y, O'Reilly MS, Marshall B et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998; 101: 1055-63.
31. Folkman J. Tumor angiogenesis: Therapeutic implications. New Engl J Med 1971; 285: 1182-6.
32. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (London) 1993; 362: 841-4.
33. Lin P, Polverini P, Dewhirst M et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie 2 in pathologic vascular growth. J Clin Invest 1997; 100: 2072-8.
34. Millauer B, Shawver LK, Plate KH et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (London) 1994; 367: 576-9.
35. Brooks PC, Stromblad S, Klemke R et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.
36. Ingber D, Fujita T, Kishimoto S et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (London) 1990; 348: 555-7.
37. Browder T, Folkman J, Shepherd SP. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-4.
38. Folkman J, Browder T, Palmblad J. Angiogenesis research: Guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23-33.
39. Good DJ, Polverini PJ, Rastinejad F et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-8.
40. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochem Biophys Acta 2000; 1477: 267-83.
41. Hiraoka N, Allen E, Apel IJ et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365-77.
42. Zhou Z, Apte SS, Soininen R et al. Impaired endochondral ossification and angiogenesis, and early lethality in mice deficient in membrane type matrix metalloproteinase I (MTI-MMP). Proc Natl Acad Sci USA 2000; 97: 4052-7.
43. Yamaguchi N, Anand-Apte B, Lee M et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999; 18: 4414-23.